ARF6 and ovarian carcinoma: Accordingly, a robust protein phosphorylation signature for PI3K‐AKT signalling was observed in Ovarian Cancer patients with high levels of ARF6‐AGAP1‐CYTH2 (specifically the PIP3‐binding CYTH22G, but not the PI(4,5)P2‐binding CYTH23G variant; Fig 7L).